Demand for Liver Transplant for NASH Set to Continue Rising

This article originally appeared here.
Share this content:
Demand for Liver Transplant for NASH Set to Continue Rising
Demand for Liver Transplant for NASH Set to Continue Rising

WEDNESDAY, Aug. 23, 2017 (HealthDay News) -- Given population obesity trends, the increase in the demand for liver transplantation (LT) for nonalcoholic steatohepatitis (NASH) noted since 2000 is expected to continue, according to a study published online Aug. 17 in Hepatology.

Neehar D. Parikh, M.D., from the University of Michigan in Ann Arbor, and colleagues examined the temporal trend behind the increase in obesity and NASH-related additions to the LT waitlist in the United States and made projections for future NASH burden on the LT waitlist. Data on the number of NASH-related LT waitlist additions were obtained from the Organ Procurement and Transplantation Network database from 2000 to 2014. During the same time period, data on the obese U.S. population were obtained from the U.S. Census Bureau and the National Health and Nutrition Examination Survey.

The researchers observed a significant increase of 44.9 percent in the proportion of obese individuals from 2000 to 2014, and the number of NASH-related annual waitlist additions increased from 391 to 1,605. In derivation and validation cohorts, there was a strong correlation for increase in the prevalence of obesity and LT waitlist additions nine years later (R² = 0.9). Between 2016 and 2030, the annual NASH-related waitlist additions were expected to increase by 55.4 percent. Significant regional variation was seen in obesity rates and the expected increase in NASH-related waitlist additions (P < 0.01).

"Continued public health efforts to curb obesity prevalence are needed to reduce the projected future burden of NASH," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »